In biotechnology and pharmaceutical companies, regulatory affairs play a central role in bringing new therapies to market. Yet many organizations struggle to distinguish between two critical regulatory functions: regulatory strategy and regulatory operations.
For biotechnology companies preparing to enter clinical development, the Pre-IND meeting with the U.S. Food and Drug Administration (FDA) is one of the most valuable opportunities for early regulatory alignment.
For biotechnology startups, reaching the point where a therapy can be tested in humans is a major milestone. The gateway to this stage is the Investigational New Drug (IND) application, which must be submitted
The Clinical Study Report (CSR) is one of the most important documents in regulatory submissions. It provides regulators with a comprehensive description of a clinical trial, including the study design, conduct, analysis, and interpretation of results.
For biotech startups, the Investigational New Drug (IND) application represents one of the most critical milestones in the drug development journey. It is the moment when a company formally requests authorization from the U.S. Food and Drug Administration (FDA) to begin testing a new drug in humans.
Bringing a therapy from development to approval is not only a scientific journey, it is a documentation journey. Health authorities do not approve intentions, effort, or potential. They approve clear, consistent, traceable evidence.
Regulatory inspections are no longer occasional events. They are a continuous state of readiness. In 2026, agencies such as the FDA, EMA, MHRA, and Health Canada are increasing expectations for data integrity, real-time documentation, supply chain transparency, and demonstrable quality culture.
Innovation moves fast. Regulation does not. For emerging biotech and pharmaceutical companies, growth often outpaces infrastructure. Teams expand, clinical programs accelerate, investors demand timelines, and partnerships multiply.
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) plays a central role in aligning regulatory expectations for the development, approval, and lifecycle management of pharmaceuticals across major global markets, including the United States, Europe, and Japan.
Antisense oligonucleotides (ASOs) represent one of the most promising classes of gene-targeting therapeutics in modern drug development.
Myocardial infarction (MI), commonly known as a heart attack, remains one of the leading causes of morbidity and mortality worldwide. Despite major advances in acute interventions
Health Canada has approved Quillivant XR (methylphenidate extended release) chewable formulation for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric and adult populations. This approval expands therapeutic options for patients who experience difficulty swallowing traditional solid oral dosage forms, addressing an important unmet clinical need.
In today’s fast-paced technological landscape, the pharmaceutical and medical device sectors stand out as leaders in adopting state-of-the-art innovations. The Food and Drug Administration (FDA) has recognized the crucial role played by Advanced Manufacturing Technologies (AMT) in shaping the future of healthcare. This article delves into the significance of the FDA’s AMT Designation. We will try …
Health Canada is responsible for developing, researching, and marketing safe and quality medications inside the territories of Canada. This federal or national agency ensures that the Canadian Drug supply is protected, and people can access the medications. This guidance, GUI-0145, is intended to reduce the drug shortage that Canada is facing in the current stages. An Interim Order respecting drug …
Health Canada is responsible for developing, researching, and marketing safe and quality medications inside the territories of Canada. This federal or national agency ensures that the Canadian Drug supply is protected, and people can access the medications. This guidance, GUI-0145, is intended to reduce the drug shortage that Canada is facing in the current stages. An Interim Order respecting drug …
In this era of technological revolution, the pharmaceutical and medical device industries are at the forefront of embracing cutting-edge innovations. The Food and Drug Administration (FDA) acknowledges the pivotal role that Advanced Manufacturing Technologies (AMT) play in shaping the future of healthcare. This blog post delves into the significance of the FDA’s Advanced Manufacturing Technology …
In this era of technological revolution, the pharmaceutical and medical device industries are at the forefront of embracing cutting-edge innovations. The Food and Drug Administration (FDA) acknowledges the pivotal role that Advanced Manufacturing Technologies (AMT) play in shaping the future of healthcare. This blog post delves into the significance of the FDA’s Advanced Manufacturing Technology …
Exploring the Revolutionary Potential of Histotripsy: A Breakthrough in Non-Invasive Tissue Ablation. Histotripsy is a breakthrough in non-invasive tissue ablation and a cutting-edge medical technology. It has great potential to revolutionize non-invasive tissue ablation procedures. Unlike traditional methods such as surgery or thermal ablation, histotripsy employs high-intensity ultrasound pulses …
A refereed paper was published on Feb 28, 2024, which focused on understanding the impact of female scent on male mice’s aging and fertility. Who knew that just sniffing around for a mate could be so risky? It looks like male mice might need some cologne and a dating app to improve their odds of a longer life! Perhaps they could call it “Eau de Fromage,” guaranteed to attract all the lady mice…
Considering the COVID-19 pandemic, the Food and Drug Administration (FDA) has introduced new guidelines and regulations to adapt to the changing landscape of the pharmaceutical industry. One significant development is the remote regulatory assessment (RRA) conducted for industry guidance by the FDA. This approach allows for conducting regulatory assessments remotely. This will result in minimizing …
Personalized medicine (PM), also known as precision medicine, acts as the “one for all’ benefit medicines derived from the specific genes of the patient undergoing the therapy. President Obama announced the Precision Medicine Initiative (PMI) in January 2015. These PMs collect data under the Human Genome Project, launched by NIH and the Department of Energy, while being established by HHS in 1989 …
The traditional “one-size-fits-all” approach to healthcare is quickly becoming outdated. Personalized medicine, a revolutionary shift towards tailoring treatments to individual patients, is emerging as the future of drug development. This exciting field leverages the power of artificial intelligence(AI) and big data to unlock the unique characteristics of each patient, which could lead to more …
The pharmaceutical industry plays a crucial role in society, developing and delivering life-saving medications. But navigating this complex field requires understanding its core principles. One framework often used to explain pharma’s foundation is the “The 5 P’s of Pharma”: People, products, processes, premises, and procedures. Understanding these 5 P’s sheds light on pharma’s intricate workings. …
In the pharmaceutical industry, Strengths, Weaknesses, Opportunities, and Threats analysis (SWOT) analysis is a strategic planning tool used to evaluate and understand the internal and external factors that can impact a company’s performance. Here’s a breakdown of each component in the context of the pharmaceutical industry: Strengths: Research and Development: Strong capabilities in R&D, with …
In the dynamic landscape of healthcare, regulatory frameworks play a pivotal role in ensuring the safety and efficacy of medical devices. The European Medicines Agency (EMA) has been at the forefront of shaping and updating regulations to meet the evolving needs of the industry. As we enter 2024, European Medicines Agency updates in the medical device regulation promise to usher in a new era of …
The pharmaceutical research and development (R&D) realm is a fascinating and complex journey transforming groundbreaking biomedical research into life-changing medications. This odyssey involves meticulous steps, from the inception of an idea to the market release of a safe and effective drug. In this comprehensive guide, we will unravel the intricacies of the drug development and drug approval …
The pharmaceutical research and development (R&D) realm is a fascinating and complex journey transforming groundbreaking biomedical research into life-changing medications. This odyssey involves meticulous steps, from the inception of an idea to the market release of a safe and effective drug. In this comprehensive guide, we will unravel the intricacies of the drug development and drug approval …
In the ever-evolving pharmaceutical and medical device industry, success is not just about innovation and breakthroughs but also about adopting and implementing best practices. Whether involved in drug development, clinical trials, regulatory affairs, or any other aspect of this dynamic field, incorporating proven strategies can significantly impact your career growth and contribute to industry …
Aging is a complex biological phenomenon influenced by genetic, environmental, and lifestyle factors. While significant research has been done on understanding the mechanisms of aging and identifying potential interventions, treatment, or therapy has yet to be universally accepted for stopping or reversing aging. Several areas of research are exploring the potential to stop the aging process or …
US FDA approval advantages for pharma companies in another country In this article, we will try to elaborate on a few tips for new pharmaceutical companies, small pharma companies, and biopharmaceutical companies in other countries to understand the advantages of US FDA approval. Also, we will discuss the importance of the FDA for their new drugs and expanding their pharmaceutical business in the …
In this article, we try to expand on “steps of New Drug Development” in general to give you an idea of the steps involved in this process and its importance. In France, six out of 90 volunteers to try a new drug went to the hospital after undergoing clinical trials, and three died of brain death. Indeed, the clinical trial of the drug has now stopped, and the drug company has called all the …
Dr. Afsaneh Motamed Khorasani has drafted a summary of what we have learned from the epidemiology of Ebola so far. Evidently, with all the progress, new findings, and observations in the field of health sciences, it is on every one of us to educate and update ourselves and ask the right questions. Please feel free to read the one-page summary at your convenience. Please feel free to read the one- …
In this post, we would like to discuss the brain-computer interface (BCI). We will explain what it is and the new advances in this field. There has been a rapid growth of studies in the area of the brain-computer interface in the last decade. Brian-Computer Interface A brain-computer interface often includes: A set of sensors to acquire neurophysiological intention signals A wired or wireless …
Catering to a global audience with a commitment to excellence in online education and training.
Peer-reviewed and up-to-date online regulatory training, ensuring professionals stay informed.
Maintaining an innovative content library as a go-to resource for the latest trends, best practices, and guidelines.
Providing an extensive library of current content to save professionals time in accessing the latest trends and information.
